SER
SER
AMEX · Biotechnology

Serina Therapeutics Inc.

$2.01
-0.08 (-3.83%)
As of Sep 28, 10:36 PM ET ·
Financial Highlights (FY 2026)
Revenue
319.2K
Net Income
-46,940,540
Gross Margin
71.8%
Profit Margin
-14,755.4%
Rev Growth
+63.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -17,921.5% -16,129.4% -27.0% -31.0%
Profit Margin -14,755.4% -14,017.6% -29.1% -28.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 319.2K 195.8K 4.38M 4.18M
Gross Profit 229.3K 140.6K 2.91M 2.78M
Operating Income -57,203,225 -31,578,790 -1,184,186 -1,293,566
Net Income -46,940,540 -25,913,320 -1,275,702 -1,196,723
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -17,921.5% -16,129.4% -27.0% -31.0%
Profit Margin -14,755.4% -14,017.6% -29.1% -28.6%
Rev Growth +63.0% +63.0% +7.3% +19.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.35M 3.27M
Total Equity — — 12.66M 11.81M
D/E Ratio — — 0.26 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -56,835,359 -33,118,806 -1,970,058 -1,901,119
Free Cash Flow — — -1,043,157 -876,007